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SUMMARY 
Ex v/vo addition of estradiol 1713 to first trimester o term human placental minces caused a significant 
increase in the quantity of progesterone produced. Addition of an aromatase inhibitor, CGS 16949 A, 
or the estrogen receptor antagonist, ICI 182780, significantly inhibited progesterone production 
confirming the role of estradiol 1713 in the regulation of progesterone synthesis in human placenta. RU
486 and ZK 98299, which are antagonists of progesterone receptor, significantly modulated 
progesterone synthesis in the human placenta butexhibited paradoxical effects on the first trimester and 
term placenta. We conclude that progesterone synthesis in thehuman placenta is regulated by estradiol 
1713 and progesterone. This is the first report providing evidence for autoregulation f progesterone 
synthesis in the human placenta. 
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INTRODUCTION 
The human placenta, besides serving the function of transport of nutrients from the maternal 
circulation to the fetus and providing protection from the attack of maternal immune system against 
the fetal semi-allograft, also serves as a very efficient endocrine gland by its ability to synthesize and 
secrete a variety of protein, peptide and steroid hormones. 
One of the most important steroid hormones produced by th  human placenta is progesterone 
(P4), which is absolutely indispensable for the maintenance of pregnancy (1). The levels of P4 
continuously increase throughout the course of pregnancy and the quantity of P4 produced by the 
Abbreviations : P4- Progesterone, E2- Estradiol 178, FTHP- First Trimester Human Placenta, 
LDL- low density lipoprotein, EBSS- Earle's Balanced Salt Solution, RIA- Radioimmunoassay. 
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human placenta can be as much as 250 - 600 mg per day during late gestation (2). The intraplacental 
concentration of P4 is estimated to be approximately as high as 7/.tM (3). However, it has little 
capacity to synthesize cholesterol, the precursor for the synthesis of P4, de novo from acetate (4). The 
human placenta obtains cholesterol from the maternal system in the form of low density lipoprotein 
{LDL} (5). Since the human placenta is completely dependent on the supply of cholesterol in the 
form of LDL from the maternal system, uptake of LDL by specific LDL receptors i  a rate limiting 
step for the synthesis of P4. However, recent studies have established that he levels of LDL-receptor 
decline with the progress of pregnancy and the e~2-macroglobulin receptor takes over the function of 
uptake of LDL during the course of pregnancy (6). 
There is very little information on the regulation of P4 synthesis a.qd the factors controlling it
in the human placenta re largely unknown. Chorionic Gonadotropin, which is known to rescue the 
corpus luteum and maintain its P4 production until the placenta cquires teroidogenic capacity, does 
not have any direct role in the regulation of P4 synthesis by human placenta (7). Feinberg et al (8) 
have reported that P4 secretion by JEG-3 choriocarcinoma cells is stimulated by cytokines like IL-1 
and TNF-et. However, these may not be the major egulatory factors as these cytokines are produced 
by monocytes upon immune-activation of these cells. Hence, this observation may not be of much 
significance in vivo. Kato et al (9) have demonstrated that phorbol esters timulate P4 production by 
human term placental explants implicating a role for Protein Kinase C and Ca 2+ in this process. 
However, the extracellular signals which might initiate these intracellular pathways are largely 
unknown. 
The placental steroids, estradiol 1713 (E2) and P4 are good candidates for regulating P4 
synthesis in the human placenta. In fact, E2 is known to facilitate the uptalke of LDL and thereby 
stimulate P4 synthesis n the baboon placenta (I0). In fact, Wunsch et al (I1) demonstrated that he 
antiestrogen, MER-25, inhibited P4 production by human placental cells cultured in vitro. However, 
subsequently it was demonstrated that MER-25 can exhibit agonistic activities (t2) and hence act like 
estrogen itself. Consequently, it is not yet clear whether estrogen stimulates or inhibits human 
placental P4 production. Our recent studies have provided unequivocal proof for the presence of 
progesterone r ceptors in the human placenta (13) and thus, human placenta is very likely a target 
tissue for the action of P4. Also, P4 synthesis has been suggested tobe under autoregulation (14). In 
the present study, we have investigated the role of P4 and E2 in the regulation of P4 production by 
the first trimester and term human placenta. Our findings reveal that both these hormones have an 
important role in regulating placental P4 production. 
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MATERIALS AND METHODS 
CGS 16949 A was a gift from Dr. A.S. Bhattiagar, Ciba-Giegy, Basel, Switzerland. ICI 
182780 was obtained from Zeneca Pharmaceuticals Chesire, England. RU 486 was obtained from 
Roussel-Uclaf, Paris, France. ZK 98299 was obtained from Schering AG, Berlin, Germany. [3H]- 
Progesterone was obtained from Amersham, UK. Aminoglutethimide was obtained from Sigma 
Chemical Co., St. Louis, USA. Estradiol 17 B was obtained from Steraloids Inc. USA. All other 
chemicals used were of analytical grade. 
Preparation of human placental minces for ex vivo incubations 
First trimester human placental minces were prepared as described earlier (15). In brief, first 
trimester human placenta (FTHP) [7-12 weeks gestation] from cases of medical termination of 
pregnancy or term placenta from cases of Caesarean section, were collected in cold Earle's balanced 
salt solution (EBSS), pH 7.2, on ice. The tissue was extensively washed with normal saline to remove 
blood contamination. The villi were separated from membranes and other tissues by visual 
examination and the villi were minced using a fine scissors. The minced villi were pelleted by 
centfifugation at500 x g, at 4~ for 2-3 minutes and after washing, the pellet was resuspended in a 
known volume of EBSS and about 50-100 mg wet weight of tissue from this preparation was 
aliquoted into the tubes and used for ex vivo studies. In order to study the effect of various modulators 
such as CGS 16949 A and RU 486, placental minces were incubated for 30 minutes in EBSS in an 
atmosphere of95% 02 and 5% CO 2 at 37~ in order to allow the endogenous steroids to be secreted 
out. In the human placenta, due to the presence of high endogenous level of steroid hormones, it is 
not possible to study the effect of added steroids. In order to overcome this problem, we have 
employed inhibitors of hormone synthesis or action to minimize the effects of endogenous hormones 
and study the effect of deprival of hormones. Following the pre-incubation, the minces were collected 
by cenlrifugation, washed with EBSS, and incubated with the desired concentration fmodulators for 
2 hours under identical conditions. The tissue was homogenized in EBSS; steroids were extracted 
with diethyl ether and used for the measurement of P4 by a radioimmunoassay (RIA). 
RIA for Progesterone 
Progesterone was estimated by a specific RIA which was standardized in our laboratory. The 
antiserum was used at a final dilution of 1:5000 and the range of the assay was 2.5 pg to 1000pg. 
The minimum detectable quantity of P4 was 15 pg. The inter-assay variation was 6.5% while the 
intra-assay variation was 2%. The extraction efficiency varied from 85-90% and the values reported 
are uncorrected for recovery. 
RESULTS 
Fresh synthesis of progesterone occurs during the ex vh, o incubation 
One of the primary requirements for the present study is to ascertain the fact that the placental 
villi are capable of synthesizing P4 during the period of incubation. In order to establish this, 
placental villi were incubated with 0.43 mM aminoglutethimide, which inhibits side-chain cleavage 
enzyme, which converts cholesterol to pregnenolone. Aminoglutethimide was able to decrease P4 
levels (data not shown) to a very significant extent in both FTHP (90% inhibition) and term placental 
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(75% inhibition) minces, confn-ming that flesh synthesis of P4 takes place during the incubation. In 
addition, externally added substrate in the form of LDL or serum also stimulated P4 production by 
the placental minces (data not shown), providing additional support for the above conclusion+ 
Further, a time course study of P4 production by placental minces revealed that P4 production is
maximal at 2 hours of incubation. Hence, the effects of all the modulators described in this study 
were examined at 2 hours of incubation. 
Effect of addition of Estradiol 17 II 
In order to investigate the role of E2, the effect of E2 was studied after inhibiting the 
endogenous biosynthesis of E2 using CGS 16949 A, an aromatase inhibitor, and then adding E2. 
Results presented inFig. 1 (a & b) demonstrate hat E2 can increase the P4 synthesis by both FTHP 
as well as term placenta in a dose-dependent manner and at near physiological concentrations. 
Effect of addition of CGS 16949 A and ICI 182780 
In order to confirm that E2 stimulates P4 synthesis, we examined the effect of CGS 16949 A, 
which is an aromatase inhibitor, and ICI 182780, which is an eslrogen receptor antagonist. Results 
presented in Fig. 2 (a & b) clearly indicate that CGS 16949 A was able to inhibit P4 production by 
FTHP as well as term placenta in a dose dependent manner. ICI 182780 (Fig.2c&d) 
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1713 on P4 production by human placental minces. 
Placental minces were incubated for 2 hours with the specified concentration f E2 in EBSS at 
37~ in an atmosphere of 95% 0 2 and 5% CO 2. Tissue was extracted with diethyl ether and the 
extract was used for the quantification of P4. (a) FTHP (b) term placenta. The values presented 
are mean ~: SEM of triplicates. The level of statistical significance is indicated over the respective 
bars. * denotes P< 0.01. 
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Figure 2 : Effect of addition of CGS 16949 A and ICI 182780 on P4 production by human 
placental minces. Experimental conditions are as described in legend to fig. 3. (a) Effect of CGS 
16949 A on P4 production by FTHP; (b) Effect of CGS 16949 A on P4 production by term 
placenta; (c)  Effect oflCI 382780 on P4 production by FTHP; and (d) Effect of ICI 382780 on 
P4 production by term placenta. * denotes P< 0.03, ** denotes P< 0.001. 
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was also able to inhibit P4 production to a very significant extent. However, while the inhibition 
observed with CGS 16949 A was dose dependent, the inhibition observed with ICI 182780 did not 
conform to such a pattern. Also, the concentration of CGS 16949 A required to bring about an 
inhibition was much higher than ICI 182780, which could be due to the high endogenous level of E2 
synthesis n the placental minces.. 
Effect of addition of RU 486 and ZK 98299 on progesterone production by FTHP 
Although our results provide additional evidence for the important role E2 has in regulating 
steroid synthesis, itwas of importance and interest to examine the role of P4, ~s it is produced in large 
quantities and as it has been suggested that P4 synthesis i  under autoregulation. However, unlike in 
the case of E2, it is not possible to study the effects of added P4 as it will interfere in the RIA. In view 
of this, we have employed antagonists of progesterone receptor, viz. RU 486 and ZK 98299. Both 
these :mtagonists did not cross-react with the antiserum and hence did not interfere in the RIA (data 
not shown). It was observed that addition of RU 486 or ZK 98299 resulted in an increase in P4 levels 
in FTHP. 1 }tM RU 486 increased P4 levels by 220% (Fig.3a) and 22.5/aM ZK 98299 caused a 
288% increase in P4 levels (Fig.3b). 
Effect of addition of RU 486 and ZK 98299 on progesterone production by term placenta 
In contrast to the stimulatory effects of anfiprogestins inFTHP, they inhibited P4 production 
in term placenta, although as expected, RU 486 (Fig.3c) was more effective (88% inhibition at 1/aM) 
as compared toZK 98299 (50% inhibition at 22.5/aM, Fig. 3d). Interestingly, the inhibitory effects of 
RU 486 and ZK 98299 were observed at the same concentrations of these compounds which 
increased P4 levels in FTHP. It is pertinent to note that while the inhibition observed in term placenta 
was concentration dependent over a wider range, the stimulation observed inFTHP was only over a 
narrow range of concentrations. 
DISCUSSION 
The synthesis of large quantities of P4 by the human placenta despite its inability to 
synthesize cholesterol and its dependence onthe maternal supply of LDL has continued to attract the 
attention of several investigators to identify the possible factors in the regulation of P4 synthesis in 
human placenta. The factors identified to date include cytokines like IGF-I, TNF- a and IL-1 (8) as 
well as intraeellular molecules like Ca 2+ and protein kinase C (9). The ability of placenta to produce 
steroid hormones like E2 and P4, which have a very crucial role to play in the maintenance of 
pregnancy, makes these hormones good candidates for regulating placental steroidogenesis. 
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Figure 3 : Effect of RU 486 and ZK 98299 on P4 production by human placental minces. 
t~xperimental conditions are described in legend to fig. 1. (a) Effect of RU 486 on P4 production 
by FTHP; (b) Effect of ZK 98299 on P4 production by FTHP; (c )  Effect of RU 486 on P4 
production by term placenta; and ( ) Effect of ZK 98299 on P4 production by term placenta. * 
denotes P< 0.01; ** denotes P< 0.001. 
The role of estrogen in the regulation of P4 production has been well studied in the case of 
baboon placenta (16). It has been demonstrated in the baboon placenta that E2 upregulates P4 
production by increasing the uptake of LDL and thereby increasing the availability of cholesterol for 
P4 synthesis (10). However, such detailed studies have not been carried out with the human placenta. 
There has been only one report on the role of E2 in P4 production by the human placenta, Wunsch et 
al (11 ) reported that the antiestrogen, MER-25 was able to inhibit P4 production by human placental 
syncytiotrophoblasts in culture. However, Cantabrana nd Hidalgo (12) demonstrated that MER-25 
can exhibit agonistic activities. Hence, therole of E2 in the regulation of P4 production by the human 
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placenta is not yet clear. We have demonstrated here that E2 can increase, in a dose dependent 
fashion, P4 synthesis in placental minces obtained ~om early (first trimester) or late (term) gestation 
during the ex vivo incubation. Further, CGS 16949 A, a potent aromatase inhibitor, and ICI 182780, a
novel, pure antiestrogen were able to inhibit P4 synthesis to a very significant extent in a dose 
dependent manner. All these observations are in agreement with Wunsch et aFs conclusion (11) and 
establish that E2 upregulates P4 synthesis in the human placenta. Recent unpublished observations 
fi:om our laboratory suggest that fiais increase is mediated by an increase in the LDL-R mRNA levels 
under the influence of E2 (17), which in turn might result in an increased uptake of LDL. 
In contrast to the studies pertaining to the role of E2, very few studies deal with the role of P4 
in the regulation of its biosynthesis. Rurmebaum and Rabe (14) have hypothesized, as early as 1983, 
that P4 synthesis in the human placenta is subject to autoregulation. The results of the present study 
suggest that P4 does indeed regulate its own synthesis. Since our approach involved 
quantification of P4 levels, it is not possible to study the effect of added P4. In order to overcome this 
problem we have employed the antiprogestins RU 486 and ZK 98299, which are progesterone 
receptor antagonists. We observed that RU 486 and ZK 98299 exhibited paradoxical effects on P4 
synthesis, i.e. they increased the levels of P4 in FTHP but decreased its levels in term placenta. 
It is well documented that both, RU 486 and ZK 98299, can exhibit agonistic effects (in 
addition to the antagonistic effects) in a cell-, stage- and gene- specific manner (18,19). Thus, it is 
possible that RU 486 and ZK 98299 kre exhibiting agonistic effects in FTHP or term placenta on P4 
production. Such paradoxical effects of antiprogestins on P4 production by corpus luteum have 
been reported uring rat pregnancy. Telleria nd Deis (20) have reported that RU 486 both raised and 
lowered P4 secretion by the corpus luteum in pregnant rats. RU 486 raised P4 secretion on Day 4 or 6 
of pregnancy, lowered it between Days 8 and 15 and again raised it between days 16 and 21. In a 
recent review, Rothchild (21) has hypothesized that P4 always stimulates its own synthesis and that 
the paradoxical effects of RU 486 are artifacts of RU 486 treatment depending on the condition of the 
corpus luteum. We have found similar paradoxical effects of RU 486 as well as ZK 98299 on P4 
synthesis by human placenta. Considering the fact that P4 is indispensable for the maintenance of 
pregnancy, it is difficult o conceive that P4 can inhibit its own production. It is possible that, as 
hypothesized in the case of corpus luteum, P4 may stimulate its own synthesis in the human placenta 
also. Such a hypothesis would explain the continuous increase in the levels of P4 throughout the 
course of gestation. Thus, the inhibitory effects of RU 486 and ZK 98299 in term placenta cou!d be 
due to their antagonistic effects while the stimulatory effect observed in FTI-IP could be due to their 
agonisfic effects. 
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While our results demonstrate that P4 does indeed regulate its own synthesis, the question as 
to whether this regulation is positive or negative is yet to be answered. Further studies aimed at 
delineating the mechanism of autoregulation ofP4 synthesis hould answer this question. 
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